CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

NCT ID: NCT03582618

Last Updated: 2023-01-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-12
• Study Completion Date: 2022-12-30

Brief Summary

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.

Detailed Description

Sorafenib is a multi-kinase inhibitor that inhibits tumor growth and angiogenesis. Although sorafenib is the first-line treatment of advanced hepatocellular cancer (HCC), patients developing resistance to sorafenib have been reported.

To meet the medical need, TaiRx, Inc. develops a new small molecule drug, CVM-1118 targeting the formation of vasculogenic mimicry (VM). VM has been associated with tumor metastasis and poor clinical outcomes. VM is reported to be particularly active in tumor under hypoxia state when patients are treated with the potent vascular endothelial growth factor (VEGF) inhibitor like sorafenib. Hence, the ability of inhibiting the VM network make CVM-1118 a potential good combination drug with sorafenib for advanced diseases.

The safety profile of CVM-1118 dosing has been established in the phase 1 study. The analysis of metabolism pathways further showed that the potential of CVM-1118 and sorafenib drug-drug interactions are very low.

Based on the mechanism of actions and the safety analysis of sorafenib and CVM-1118, the design of phase 2 trial with the combination therapy might have great potential for the patients with advanced HCC.

Conditions

Hepatocellular Carcinoma; Advanced Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sorafenib + CVM-1118

Cycle 0 (at least 3 weeks): sorafenib tolerability assessment period (sorafenib alone)

400mg BID daily (starting dose); The subject will be assessed for the need for a dose reduction in sorafenib during this period.

Cycle 1+ (28-day cycles): combination period (sorafenib+CVM-1118)

Tolerable dose of sorafenib and CVM-1118 150 (starting dose) or 200 mg BID will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal.

Group Type: EXPERIMENTAL

Sorafenib

Intervention Type: DRUG

Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period

CVM-1118

Intervention Type: DRUG

CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle

Interventions

Sorafenib

Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period

Intervention Type: DRUG

CVM-1118

CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle

Intervention Type: DRUG

Other Intervention Names

Nexavar; TRX-818

Eligibility Criteria

Inclusion Criteria

1. Signed, informed consent

2. Age 18 or older (for all treatment locations with exception of Taiwan), or age 20 or older (Taiwan only)

3. Pathologically or cytologically-confirmed, advanced-stage hepatocellular carcinoma without prior systemic treatment except for prior immunotherapy and Child-Pugh liver function class A appropriate for treatment with sorafenib

4. Measurable disease according to modified Response Evaluation Criteria in Solid Tumors criteria (mRECIST)

5. Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 1

6. Adequate laboratory parameters including:

1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN), or AST and ALT ≤ 5.0 x ULN if liver function abnormalities are due to underlying malignancy

2. Total serum bilirubin ≤ 2.0 x ULN (except for subjects with documented Gilbert's syndrome who have a limit of ≤ 3.0 x ULN)

3. Absolute neutrophil count (ANC):1500/µL

4. Platelets: 90,000/µL

5. Hemoglobin: 9.0 g/dL

6. Serum creatinine ≤ 2.0 x ULN or creatinine clearance of ≥ 50 mL/min

7. Serum albumin ≥ 3.0 g/dL

8. International normalized ratio (INR) ≤ 1.4

9. Prothrombin Time (PT)/ Activated Partial Thromboplastin Time (aPTT) ≤ 1.2 x ULN

7. QTc interval (using Fridericia correction) of ≤ 470 msec (QTc interval may be derived from up to 3 separate EKGs performed at least 5 minutes apart)

8. Willingness to participate in collection of pharmacokinetic and other exploratory blood collection as defined in the protocol

9. Willingness to use adequate contraception throughout study and for a period of 3 months after last dose of CVM-1118

Exclusion Criteria

1. Major surgery (other than diagnostic surgery) or radiation therapy within 28 days of starting study treatment

2. Prior systemic immunotherapy for hepatoma within 28 days of starting study treatment

3. Systemic anticancer therapy (e.g., chemotherapy, hormonal, investigational, biological therapies) within 28 days (or fewer than 5 half-lives, whichever is shorter) of starting study treatment except for ongoing hormonal therapy administered for control of a second cancer (e.g., breast or prostate cancer)

4. Receipt of a CYP3A4 inducer less than 28 days or 5 half-lives of the CYP3A4 inducer prior to the first day of sorafenib administration

5. Other known active cancer(s) likely to require treatment in the next two (2) years or likely to impact the assessment of any study endpoints

6. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy (e.g., subjects with known HBV or HCV infections controlled on antivirals are allowed)

7. Known Central Nervous system (CNS) metastases unless appropriately treated and neurologically stable for ≥ 4 weeks off steroids

8. Pregnant or currently breast-feeding

9. Known HIV-positive

10. Patients with impaired gastrointestinal (GI) diseases that may significantly alter the absorption of oral medications

11. Psychiatric illness/social situations that would interfere with compliance with study requirements

12. History of clinically significant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure (New York Heart Association classification ≥ 2), unstable angina, poorly controlled arrhythmias, myocardial infarction within 6 months of study entry

13. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgement of the PI and/or Sponsor, excess risk associated with study participation or study drug administration, which would make the subject inappropriate for entry into this study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

TaiRx, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Charleston Hematology Oncology Associates

Charleston, South Carolina, United States

National Cheng Kung University Hospital

Tainan City, , Taiwan

National Taiwan University Hospital

Taipei, , Taiwan

Countries

United States; Taiwan

Other Identifiers

CVM-004

Identifier Type: -

Identifier Source: org_study_id